Many inflammatory disease processes induce fibroblast recruitment, leaving behind fibrosis in their wake; NASH is one such disease. The hallmark of NASH is fat deposition and fibrosis in the liver in the absence of excessive alcohol consumption, and it is closely tied to metabolic dysregulation. The Scientist is bringing together a panel of experts to discuss the industry-wide trends in cell signaling analysis and molecular pharmacology that are informing the search for NASH therapies, to explore the challenges of identifying therapeutic targets for multifactorial, lifestyle-induced diseases, and to share the latest details of their NASH-directed R&D efforts. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.
Topics to be covered:
- Current thinking on NASH etiology and the best approaches for drug-discovery efforts
- Diagnosing and tracking NASH-induced diseases with noninvasive biomarkers
- Targeting the Liver X Receptor (LXR)...
Meet the Speakers:
Arun Sanyal, MBBS, PhD
Professor, Departments of Medicine, Physiology, and Molecular Pathology
Virginia Commonwealth University
Manuela G. Neuman, MSc, PhD, FCAB
Professor, Department of Pharmacology and Toxicology, University of Toronto
Chief Executive Officer, In Vitro Drug Safety and Biotechnology, Banting Institute
Thomas P. Burris, PhD
Professor and Chair,
Department of Pharmacology and Physiology
Saint Louis University School of Medicine